STMN1, SMARCC1, ALDOA, CLTC, PSMG1, SUZ12, DAG1, PGRMC1, and HMGCR, and MYO10 were upregulated following compound treatment Additionally, the compounds against Alzheimer’s disease were identified and their BBB permeability levels were predicted. This evidence concerns the gene MYO10 and early-onset autosomal dominant Alzheimer disease.